CA2158869A1 - Recombinant virus, process for preparing the same and use thereof in gene therapy - Google Patents

Recombinant virus, process for preparing the same and use thereof in gene therapy

Info

Publication number
CA2158869A1
CA2158869A1 CA002158869A CA2158869A CA2158869A1 CA 2158869 A1 CA2158869 A1 CA 2158869A1 CA 002158869 A CA002158869 A CA 002158869A CA 2158869 A CA2158869 A CA 2158869A CA 2158869 A1 CA2158869 A1 CA 2158869A1
Authority
CA
Canada
Prior art keywords
preparing
same
gene therapy
recombinant virus
cancers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002158869A
Other languages
French (fr)
Other versions
CA2158869C (en
Inventor
Hedi Haddada
Evelyne May
Michel Perricaudet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Hedi Haddada
Evelyne May
Michel Perricaudet
Rhone-Poulenc Rorer S.A.
Aventis Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9304745A external-priority patent/FR2704234B1/en
Application filed by Hedi Haddada, Evelyne May, Michel Perricaudet, Rhone-Poulenc Rorer S.A., Aventis Pharma S.A. filed Critical Hedi Haddada
Publication of CA2158869A1 publication Critical patent/CA2158869A1/en
Application granted granted Critical
Publication of CA2158869C publication Critical patent/CA2158869C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
    • C12N2710/10241—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Abstract

La présente invention concerne des adénovirus recombinants comportant une séquence d'ADN hétérologue, leur préparation, et leur utilisation pour le traitement et/ou la prévention des cancers.The present invention relates to recombinant adenoviruses comprising a heterologous DNA sequence, their preparation and their use for the treatment and / or prevention of cancers.

CA002158869A 1993-04-22 1994-04-15 Recombinant virus, process for preparing the same and use thereof in gene therapy Expired - Lifetime CA2158869C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR93/04745 1993-04-22
FR9304745A FR2704234B1 (en) 1993-04-22 1993-04-22 RECOMBINANT VIRUSES, PREPARATION AND USE IN GENE THERAPY.
PCT/FR1994/000421 WO1994024297A1 (en) 1993-04-22 1994-04-15 Defective recombinant adenoviruses for gene therapy of tumours

Publications (2)

Publication Number Publication Date
CA2158869A1 true CA2158869A1 (en) 1994-10-27
CA2158869C CA2158869C (en) 2007-07-03

Family

ID=38246505

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002158869A Expired - Lifetime CA2158869C (en) 1993-04-22 1994-04-15 Recombinant virus, process for preparing the same and use thereof in gene therapy

Country Status (1)

Country Link
CA (1) CA2158869C (en)

Also Published As

Publication number Publication date
CA2158869C (en) 2007-07-03

Similar Documents

Publication Publication Date Title
TW260708B (en)
CA2011878A1 (en) Immunogenic regions on the e7 protein of human papillomavirus type 16
IL118259A0 (en) Recombinant viral vector system
FR2738151B1 (en) ANTAGONISTS OF THE ONCOGENIC ACTIVITY OF THE MDM2 PROTEIN, AND THEIR USE IN THE TREATMENT OF CANCERS
FR2716682B1 (en) Process for the preparation of recombinant adeno-associated viruses (AAV) and uses thereof.
AUPO784197A0 (en) Treatment of nasopharyngeal carcinoma
CA2050304A1 (en) Pharmaceutical composition useful in preventing or treating tumors induced by papillomaruses
CA2000786A1 (en) 3-piperidinyl-1,2-benzisoxazoles
EP1005376A4 (en) Methods and compositions for use in gene therapy for treatment of hemophilia
AU1348083A (en) Dna sequences, recombinant dna molecules and preparations of cholera toxin
AU2006092A (en) Recombinant virus expressing carcinoembryonic antigen and methods of use thereof
BG102343A (en) Recombinant anti-cd4 antibodies for therapy in hyman medicine
MY101852A (en) Tumor necrosis factor, methods for its preparation, containing it, dna encoding it and assay method using such dna.
FR2730504B1 (en) PROCESS FOR THE PREPARATION OF RECOMBINANT ADENOVIRUS GENOMES
CA2155017A1 (en) Vpr function and activity
WO1996031607A3 (en) Use of an 'immunodeficiency-virus suppressing lymphokine (isl)' to inhibit the replication of viruses, in particular of retroviruses
EP0868522A4 (en) Recombinant poxvirus-feline infectious peritonitis virus, compositions thereof and methods for making and using them
AU7440087A (en) Process for isolating and purifying p. falciparum cs protein vaccine expressed in recombinant e. coli
MX9806041A (en) PURIFIED SR-p70 PROTEIN.
AU2458988A (en) The preparation, by genetic manipulation, of anticoagulative protein pp4
CA2158869A1 (en) Recombinant virus, process for preparing the same and use thereof in gene therapy
FR2724320B1 (en) NEW IMPLANT FOR THE TREATMENT OF ACQUIRED DISEASES
EP0254593A3 (en) Preparation and uses of interferon-gamma
CA2184297A1 (en) Recombinant viruses coding for a glutamate decarboxylase (gad) activity
AU4312093A (en) Use of a hymenoptera venom for the manufacture of a medicament for treating dna virus infections

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20140415